A detailed history of Captrust Financial Advisors transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 10,174 shares of ALDX stock, worth $55,855. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,174
Previous 10,039 1.34%
Holding current value
$55,855
Previous $32,000 3.13%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.25 - $4.72 $438 - $637
135 Added 1.34%
10,174 $33,000
Q1 2024

May 15, 2024

SELL
$2.77 - $4.22 $26,184 - $39,891
-9,453 Reduced 48.5%
10,039 $32,000
Q4 2023

Feb 14, 2024

SELL
$1.47 - $6.06 $16,075 - $66,272
-10,936 Reduced 35.94%
19,492 $68,000
Q3 2023

Nov 14, 2023

BUY
$6.11 - $8.16 $93,721 - $125,166
15,339 Added 101.66%
30,428 $203,000
Q2 2023

Aug 14, 2023

BUY
$7.11 - $11.89 $107,282 - $179,408
15,089 New
15,089 $126,000
Q2 2022

Aug 16, 2022

SELL
$2.43 - $4.85 $439 - $877
-181 Reduced 14.25%
1,089 $4,000
Q1 2022

May 16, 2022

BUY
$3.25 - $5.17 $2,502 - $3,980
770 Added 154.0%
1,270 $6,000
Q4 2021

Feb 14, 2022

BUY
$3.5 - $9.63 $1,750 - $4,815
500 New
500 $2,000

Others Institutions Holding ALDX

About Aldeyra Therapeutics, Inc.


  • Ticker ALDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,323,100
  • Market Cap $320M
  • Description
  • Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...
More about ALDX
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.